TNFRSF17 and plasma cell myeloma: Teclistamab-cqyv (TecvayliTM), which targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma B-lineage cells, is used for the treatment of relapsed/refractory multiple myeloma.